Aflibercept 8 mg/0.07 mL (Eylea HD)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses aflibercept (Eylea HD) 8 mg (0.07 mL), solution for intravitreal injection. Indication: For the treatment of neovascular (wet) age-related macular degeneration (nAMD).